Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2009

View Archived Issues

Adenoviral delivery of alpha-sarcoglycan may be a promising therapy for muscular dystrophy

Botulinum toxin type B safe over 7 years in patients with cervical dystonia

Glycopyrronium bromide significantly improves sialorrhea in Parkinson's disease patients

AstraZeneca discloses novel prostaglandin E synthase-1 inhibitors for osteoarthritis therapy

Schering-Plough describes RNA-directed RNA polymerase inhibitors for the treatment of hepatitis C

Cis-urocanic acid emulsion improves skin barrier function in acute irritant dermatitis phase I study

DMMET-01 improves metabolic control in naive type 2 diabetes patients

3-Month extension of review period expected for Intermezzo NDA

Millennium Pharmaceuticals claims IKK-2 inhibitors for the treatment of rheumatoid arthritis

Bristol-Myers Squibb describes NS5B polymerase inhibitors for HCV

RGI-2001 in combination with low-dose sirolimus induces donor-specific transplantation tolerance

AEterna opens extended study for cetrorelix in benign prostatic hyperplasia

Cytos initiates combined phase I/IIa study with anti-interleukin-1 beta vaccine

Caldolor is first FDA approved intravenous therapy for fever

ImmunoGen seeks to outlicense discontinued compound IMGN-242

Modigene approves company name change to Prolor Biotech

Abraxane now available in China

Xenon and Merck & Co. establish cardiovascular strategic alliance

Takeda presents 5-HT2C receptor agonists for the treatment of obesity

G-15, a highly selective GRP30 antagonist, may be useful in the regulation of estrogen signaling

Genzyme receives European approval of Renvela for chronic kidney disease

Icagen completes enrollment in phase II senicapoc trial in exercise-induced asthma

FDA expected to approve REMS for Meda's cancer pain drug Onsolis in summer 2009

Merck & Co. to update prescribing information for Singulair following FDA communication

BSI and Lohocla sign licensing agreement for alcoholism liver disease biomarkers

Archimedes and Almac sign licensing and development agreement for granisetron product

St. Jude Medical to sponsor CABANA trial of catheter ablation in atrial fibrillation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...